A standalone M&A theme focused on acquiring plasma energy technology through the acquisition of RetroVascular and combining it with existing technology for applications in CTO (chronic total occlusion) and peripheral vascular treatment. Development of a plasma wire system was abandoned, but exploration of other applications is ongoing.